📅 PUBMED DAILY TRIAGE — 2026-05-28

Window: 2026-05-27T09:00Z → 2026-05-28T09:00Z (CRDT)
Topics scanned: 10 | Candidates evaluated: ~97 | Articles classified: 19
High priority: 7 | Standard: 10 | Low/archive: 2 | Unsolicited finds: 2
Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic malignancies + CBC/ML Hematology (cross-topic)

TR-2026-05-28-001 / PMID 42203504 · Interpretable ML model using peripheral blood for non-invasive detection of moderate-to-severe myelofibrosis in JAK2 V617F-positive MPNs · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
→ SVM model on peripheral blood (Hb, IL-1β, age) detects moderate-to-severe MF with AUC 0.916 in external validation (n=428 total); IL-1β reversal by ruxolitinib/pegIFN-α adds mechanistic depth. Multicentre pilot — non-invasive staging could reduce invasive BM biopsy burden for regular MPN monitoring.
Br J Haematol — Hao Z / Shanxi Medical University + Case Western Reserve

Early cancer detection / Liquid biopsy (see also: Precision oncology for HRDetect)

TR-2026-05-28-003 / PMID 42202254 · Detection of Ultralow-Frequency ctDNA Mutations Using a Dual Hairpin-Competition CRISPR/Cas14a System · 7/10 · 🔴 EARLY_CANCER_DETECTION
→ DHCC platform detects ctDNA at 0.002% VAF (250-fold gain over prior Cas14a; 58-fold improvement in discrimination); 100% concordance with ddPCR in 22 plasma samples on standard qPCR hardware. Potentially democratizes ultrasensitive liquid biopsy.
Anal Chem — Liu Z / Nanjing Medical University

TR-2026-05-28-004 / PMID 42202925 · Emerging Biomarkers for the Early Detection of High-Grade Serous Tubo-Ovarian Cancer · 6/10 · 🔴 EARLY_CANCER_DETECTION
→ Systematic review endorses DNA methylation-based liquid biopsy as strongest current evidence for HGSOC screening; no existing biomarker reduces mortality at population level. High-unmet-need area synthesized for multimodal approach development.
Crit Rev Oncol Hematol — Atiq S / University of Newcastle

TR-2026-05-28-005 / PMID 42202492 · ctDNA profiling + anti-EGFR history predicts dual HER2 therapy failure in HER2-amplified mCRC (TRIUMPH/MyPathway) · 6/10 · 🟠 NOVEL_TREATMENT
→ ctDNA resistance alterations (RAS/BRAF/PIK3CA) in 27.3% of patients predicted 0% objective response to pertuzumab+trastuzumab and median OS 7.6 vs 16.5 months (HR 2.15). Actionable patient selection framework for HER2-targeted mCRC.
ESMO Open — Nakamura Y / National Cancer Center Hospital East, Tokyo

Precision oncology / Genomic medicine

TR-2026-05-28-002 / PMID 42201779 · HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications · 8/10 · 🟠 NOVEL_TREATMENT
→ WGS HRDetect-high OC had OS 6.2 vs 4.1 years (HR 0.60, p=0.007); in ARIEL2 validation, PARPi response rate 54% vs 22.5% (HR 0.44, p=0.03); 23.2% HRDetect-intermediate category reveals underappreciated genomic heterogeneity. Precision PARPi selection beyond binary HRD.
Clin Cancer Res — Nik-Zainal S / Swisher EM (Cambridge + Fred Hutch/UW), n=262

Rare diseases / Novel therapeutics

TR-2026-05-28-006 / PMID 42202045 · Controlled CRISPR genome editing (PRINCE/Little Prince) for hypercholesterolemia and neovascular AMD · 5/10 (capped, non-human) · 🟠 NOVEL_TREATMENT
→ Small-molecule-inducible PRINCE/Little Prince systems: 45-47% LDL reduction in humanized mouse models, AMD lesion reduction (p<0.0001), dramatically reduced off-target editing vs constitutive CRISPR. 2-year temporal precision in human cell cultures. Single-AAV delivery for rare disease gene therapy.
Sci Transl Med — Zhang J / Wang Y (Shenzhen + Fudan)

💡 Sentinel / Unsolicited HIGH

TR-2026-05-28-007 / PMID 42204136 · Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy · 6/10 · 🟠 NOVEL_TREATMENT (unsolicited)
→ RNA therapy reverses phospholamban cardiomyopathy-specific signaling dysregulation identified by phosphoproteomics — a rare genetic cardiomyopathy with high sudden death risk and no approved disease-modifying therapy. High-impact journal (Signal Transduct Target Ther, IF ~39) from van der Meer P (Groningen).
Signal Transduct Target Ther — Deiman FE / van der Meer P (UMCG)

🟢⚪ STANDARD (4–7) — Top by Topic

Hematologic malignancies

• TR-008 / PMID 42203583 · Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis · 5/10 · Diagnostics
  n=350, retrospective; thrombocytosis in pre-PMF: adjusted HR 7.80 for death (p=0.015). Platelet count as pragmatic risk stratifier. Clin Lymphoma Myeloma Leuk
• TR-009 / PMID 42203338 · Immunogenomics of Endemic Burkitt Lymphoma: Relevance to Outcomes · 5/10 · Genomics/Precision Medicine (🟡 UNDERSERVED_POPULATION)
  Landscape analysis; sub-Saharan Africa pediatric lymphoma. Anticancer Research
• TR-016 / PMID 42203479 · Clonal hematopoiesis and circulating biomarkers in cardiovascular diseases · 4/10 · Diagnostics
  Review bridging CHIP + CVD. Fukushima J Med Sci

AI/ML in clinical diagnostics

• TR-010 / PMID 42204240 · Personalised VTE risk prediction after endometrial cancer surgery (explainable AI + SHAP) · 6/10 · Diagnostics (🟢 NEAR_TERM_IMPLEMENTABLE)
  SVM AUC 0.828/0.819 internal/external, n=841 multi-center, 4-variable model, web deployment. NPJ Digital Medicine
• TR-011 / PMID 42204233 · AI Hybrid CNN-Transformer for diabetic retinopathy grading · 5/10 · Diagnostics
  AUC-ROC 0.981 on benchmark datasets. Sci Reports

Cardiovascular-metabolic

• TR-013 / PMID 42201355 · Semaglutide and NAION risk in T2DM: systematic review & meta-analysis · 6/10 · Public Health
  Timely pharmacovigilance synthesis for one of the most-prescribed drugs globally. Graefes Arch
• TR-012 / PMID 42199788 · Dapagliflozin + HRV decline in T2DM on GLP-1 therapy: prospective observational · 5/10 · Diagnostics
  Novel SGLT2i + GLP-1 RA combination autonomic signal; PMC open access. Front Endocrinol

Precision oncology

• TR-014 / PMID 42203742 · ITSN1-ALK fusion PDAC with 19-month alectinib PFS (case report) · 4/10 · Treatment Innovation (⚪ PROMISING_PRELIMINARY)
  First ALK fusion in PDAC; NGS guided actionable therapy, patient alive at month 29. Oncologist

Rare diseases / Diagnostics

• TR-015 / PMID 42201636 · Alpha-synuclein SAA multicenter 2×2 validation (MSA/PD/DLB) · 5/10 · Diagnostics
  SPB vs PIPES conditions: distinct sensitivity profiles for MSA vs PD/DLB; high inter-site concordance. Neurol Ther, n=60

Unsolicited (STANDARD)

• TR-017 / PMID 42204170 · Long-term spatiotemporal evolution of drug-resistant M. tuberculosis in China · 6/10 · Public Health (unsolicited)
  WGS phylogenomics, Nat Commun, Gagneux S. Outside watchlist but noted.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 2
• Diagnostics: 8
• Treatment Innovation: 3
• Drug Development: 2
• Genomics/Precision Medicine: 2
• Public Health: 2

By evidence maturity:

• Exploratory: 10
• Validated: 7
• Potentially Practice-Changing: 0

By watchlist topic — reviewed / classified / highest score:

*cross-topic with Hematologic malignancies

By source type: peer_reviewed 19 | preprint 0

Topics with zero 8+ articles this run:

• AI/ML in clinical diagnostics
• Cardiovascular-metabolic
• Aging/longevity (sparse — human filter applied, candidates dominated by non-aging mechanistic studies)

🔧 RUN NOTES

• CBC/ML sparse streak broken: PMID 42203504 (Br J Haematol) matches both Hematologic malignancies and CBC/ML hematology — first high-priority CBC/ML article after 12+ consecutive sparse runs.
• Aging/longevity: humans[MeSH] filter applied per v1.2 protocol note. Despite 140 results, top 10 candidates were dominated by non-aging mechanistic papers (exosomal miRNA, T-lymphocyte apoptosis) matching via 'senescence' term. Zero classified in this topic. Query may need further refinement to exclude non-human-aging mechanistic biology (e.g., add AND ("aging"[MeSH] OR "longevity"[MeSH]) as MeSH subheader).
• Deferred PMID 42185479 (Nat Cancer, CNS leukemia copper metabolism, non-human preclinical from 2026-05-27): carried forward for Phase 2 full-text review; not re-evaluated in today's window.
• No window expansion triggered — 19 relevant records > 5 threshold.
• No truncation of kept records — all per-topic caps met; highest-value articles prioritized.
• Alerts sent: 5 Telegram alerts (TR-001, TR-002, TR-003, TR-004, TR-007). TR-005 and TR-006 HIGH priority but not alerted (5-alert cap reached; prioritized highest scores and most unique signals).
• Rolling 7-day topic signal trend (from state): CBC/ML hematology sparse streak broken today; Aging/longevity: 7th+ consecutive sparse run (needs query refinement).